Full Press Release Details
WASHINGTON , May 14, 2026 /PRNewswire/ -- A new global survey of patient and urologist perception and experience—conducted in collaboration with leading bladder cancer professional and patient organizations—reveals the physical, mental, and emotional toll associated with standard-of-care therapies for bladder cancer, including surgery to remove the bladder and Bacillus Calmette-Guérin (BCG) treatment. Released ahead of the American Urological Association (AUA) Annual Meeting, the findings highlight patient experiences that may not always be fully surfaced and discussed during care, pointing to opportunities to strengthen support and continue advancing innovative treatment approaches.
The survey was conducted by The Harris Poll on behalf of Johnson & Johnson (NYSE: JNJ ) in collaboration with the International Bladder Cancer Group (IBCG), the World Bladder Cancer Patient Coalition (WBCPC), and the Bladder Cancer Advocacy Network (BCAN), and examined the experiences of 817 patients with non–muscle-invasive bladder cancer (NMIBC) and 802 urologists across six countries: the United States, Mexico, Brazil, Japan, Germany, and France.
Additional Survey Findings
Learn more about what the survey reveals about the lived experience of bladder cancer at jnj.com/BladderBurdenSurvey .
The research was conducted online within the United States, Brazil, France, Germany, Japan, and Mexico by The Harris Poll on behalf of Johnson & Johnson among 817 NMIBC patients (i.e., adults aged 18 or older who have been diagnosed by an HCP with bladder cancer, have specifically been diagnosed with NMIBC, and have a urologist who is primarily responsible for treating their bladder cancer) and 802 urologists who see/treat NMIBC patients (i.e., adults aged 18 or older who are a physician specializing in urology, who see/treat at least 1 bladder cancer patient in a typical month, and who have seen/treated at least 1 NMIBC patient in the last 3 months). The survey was conducted November 25 to December 29, 2025. Individual countries are combined with a post weight to give each country an equal proportion of the total. Patients and physicians who qualified for and successfully completed the survey were compensated for their participation.
For complete survey methodology, including weighting variables and subgroup sample sizes, please contact [email protected] .
About Harris Poll
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
*Alex Filicevas has provided consulting, advisory, and media support to Johnson & Johnson.
**Ashish M. Kamat, M.D., MBBS, FACS, has provided consulting, advisory, and media support to Johnson & Johnson.
***Meri-Margaret Deoudes has provided consulting, advisory, and media support to Johnson & Johnson.